The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis.

IF 11.5 1区医学 Q1 DERMATOLOGY

JAMA dermatology Pub Date : 2024-08-01 DOI:10.1001/jamadermatol.2024.1987

Meredith Tyree Polaskey, Christy H Chang, Karishma Daftary, Sheiva Fakhraie, Corinne H Miller, Raj Chovatiya

{"title":"The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis.","authors":"Meredith Tyree Polaskey, Christy H Chang, Karishma Daftary, Sheiva Fakhraie, Corinne H Miller, Raj Chovatiya","doi":"10.1001/jamadermatol.2024.1987","DOIUrl":null,"url":null,"abstract":"Importance: Seborrheic dermatitis is a prevalent chronic inflammatory skin disease, yet its global prevalence, pathogenesis, and epidemiology remain inadequately defined.Objective: To provide a detailed estimation of the global prevalence of seborrheic dermatitis, analyze demographic variations, and explore differences in various settings.Data sources: Embase, PubMed, Scopus, and Cochrane Database of Systematic Reviews were searched from inception through October 2023.Study selection: Original investigations on seborrheic dermatitis prevalence were included after duplicate screening of titles, abstracts, and full articles, including only studies with clinician-diagnosed cases.Data extraction and synthesis: Following PRISMA guidelines, data were extracted and quality was assessed independently by multiple reviewers. A random-effects model using restricted maximum likelihood was used for meta-analysis and subgroup analyses.Main outcome and measure: The primary outcome was the pooled estimate of global seborrheic dermatitis prevalence.Results: From 1574 identified articles, 121 studies were included, encompassing 1 260 163 individuals and revealing a pooled global seborrheic dermatitis prevalence of 4.38% (95% CI, 3.58%-5.17%), with significant heterogeneity (I2 = 99.94%). Subgroup analyses showed variations by age, with a higher prevalence in adults (5.64% [95% CI, 4.01%-7.27%]) compared to children (3.70% [95% CI, 2.69%-4.80%]) and neonates (0.23% [95% CI, 0.04%-0.43%]). Geographic analyses indicated variability, with the highest prevalence in South Africa (8.82% [95% CI, 3.00%-14.64%]) and the lowest in India (2.62% [95% CI, 1.33%-3.92%]).Conclusions and relevance: This comprehensive meta-analysis provides a detailed estimation of the global prevalence of seborrheic dermatitis, highlighting significant variability across different demographics and settings.","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223058/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2024.1987","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Importance: Seborrheic dermatitis is a prevalent chronic inflammatory skin disease, yet its global prevalence, pathogenesis, and epidemiology remain inadequately defined.

Objective: To provide a detailed estimation of the global prevalence of seborrheic dermatitis, analyze demographic variations, and explore differences in various settings.

Data sources: Embase, PubMed, Scopus, and Cochrane Database of Systematic Reviews were searched from inception through October 2023.

Study selection: Original investigations on seborrheic dermatitis prevalence were included after duplicate screening of titles, abstracts, and full articles, including only studies with clinician-diagnosed cases.

Data extraction and synthesis: Following PRISMA guidelines, data were extracted and quality was assessed independently by multiple reviewers. A random-effects model using restricted maximum likelihood was used for meta-analysis and subgroup analyses.

Main outcome and measure: The primary outcome was the pooled estimate of global seborrheic dermatitis prevalence.

Results: From 1574 identified articles, 121 studies were included, encompassing 1 260 163 individuals and revealing a pooled global seborrheic dermatitis prevalence of 4.38% (95% CI, 3.58%-5.17%), with significant heterogeneity (I2 = 99.94%). Subgroup analyses showed variations by age, with a higher prevalence in adults (5.64% [95% CI, 4.01%-7.27%]) compared to children (3.70% [95% CI, 2.69%-4.80%]) and neonates (0.23% [95% CI, 0.04%-0.43%]). Geographic analyses indicated variability, with the highest prevalence in South Africa (8.82% [95% CI, 3.00%-14.64%]) and the lowest in India (2.62% [95% CI, 1.33%-3.92%]).

Conclusions and relevance: This comprehensive meta-analysis provides a detailed estimation of the global prevalence of seborrheic dermatitis, highlighting significant variability across different demographics and settings.

查看原文本刊更多论文

脂溢性皮炎的全球患病率：系统回顾与元分析》。

重要性：脂溢性皮炎是一种流行的慢性炎症性皮肤病，但其全球流行率、发病机制和流行病学仍未得到充分界定：详细估算脂溢性皮炎的全球患病率，分析人口统计学差异，探讨不同环境下的差异：数据来源：检索了从开始到 2023 年 10 月的 Embase、PubMed、Scopus 和 Cochrane 系统综述数据库：研究选择：对标题、摘要和全文进行重复筛选后，纳入有关脂溢性皮炎患病率的原创性研究，仅包括临床医生诊断病例的研究：按照 PRISMA 指南提取数据，并由多位审稿人对数据质量进行独立评估。在进行荟萃分析和亚组分析时，采用了限制性最大似然法随机效应模型。主要结果和测量指标：主要结果是全球脂溢性皮炎患病率的汇总估计值：从 1574 篇已确定的文章中，纳入了 121 项研究，涉及 1 260 163 人，汇总的全球脂溢性皮炎患病率为 4.38%（95% CI，3.58%-5.17%），具有显著的异质性（I2 = 99.94%）。亚组分析显示了不同年龄段的差异，成人（5.64% [95% CI, 4.01%-7.27%]）的患病率高于儿童（3.70% [95% CI, 2.69%-4.80%]）和新生儿（0.23% [95% CI, 0.04%-0.43%]）。地域分析表明存在差异，流行率最高的是南非（8.82% [95% CI, 3.00%-14.64%] ），最低的是印度（2.62% [95% CI, 1.33%-3.92%] ）：这项综合荟萃分析详细估算了脂溢性皮炎的全球患病率，突出显示了不同人口和环境中的显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA dermatology DERMATOLOGY-

CiteScore

14.10

自引率

5.50%

发文量

300

期刊介绍： JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.